UK's Johnson Matthey picks DS Smith's Pike as next CFO-February 2024-www.financetom.com

UK's Johnson Matthey picks DS Smith's Pike as next CFO

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

UK's Johnson Matthey picks DS Smith's Pike as next CFO

Feb 9, 2025 11:18 PM

Feb 10 (Reuters) - British autocatalyst maker Johnson

Matthey ( JMPLF ) on Monday said it had appointed DS Smith's ( DITHF )

Richard Pike as its next finance chief and that Chairman Patrick

Thomas will be stepping down from his role.

Previous page： --HSBC Gets SVB Trade-Secret Lawsuit Trimmed Down Next page： Exscientia Expands Amazon Web Services Partnership to Support Drug Discovery Platform

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

--HSBC Gets SVB Trade-Secret Lawsuit Trimmed Down

Jul 10, 2024

08:35 AM EDT, 07/10/2024 (MT Newswires) -- Price: 43.01, Change: +0.03, Percent Change: +0.07 ...

Exscientia Expands Amazon Web Services Partnership to Support Drug Discovery Platform

Jul 10, 2024

08:38 AM EDT, 07/10/2024 (MT Newswires) -- Exscientia ( EXAI ) said Wednesday it has expanded its collaboration with Amazon (AMZN) Web Services to integrate artificial intelligence and machine learning services into its drug discovery platform. The drug discovery company said its platform uses AWS technologies to integrate AI drug design and robotic lab automation, aiming to support the development...

Virpax Says Non-Narcotic Pain Medication Shows Positive Results in Swine Model Study; Shares Rise

Jul 10, 2024

08:34 AM EDT, 07/10/2024 (MT Newswires) -- Virpax Pharmaceuticals ( VRPX ) on Wednesday reported positive results in a swine model pilot study of Probudur, the company's liposomal bupivacaine formulation to provide both immediate and extended pain relief. Probudur was injected into four juvenile domestic pigs at a dose of 30 mg per kilogram and was well-tolerated and demonstrated a...

Kazia Therapeutics' Phase 2/3 Trial for Paxalisib in Glioblastoma Brain Cancer Shows Clinically Significant Improvement

Jul 10, 2024

08:32 AM EDT, 07/10/2024 (MT Newswires) -- Kazia Therapeutics ( KZIA ) said Wednesday a phase 2/3 trial has shown that its investigational brain disease treatment, paxalisib, causes clinically significant improvement in overall survival for patients with glioblastoma, a life-threatening brain cancer. Paxalisib showed an approximate 33% improvement in the overall survival of newly diagnosed patients with glioblastoma, compared with...